Source: GlobalNewswire

Press Release: Sitryx : Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis

Read full article »

Sitryx's Competitors | Sitryx's News | Sitryx's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Neil Weir

CEO Approval Rating

86/100

Sitryx is an England-based biopharmaceutical company that researches and develops immune cell metabolism therapies for the treatment of chronic autoimmune diseases and cancer.